Literature DB >> 26350029

Meta-analysis of radical resection rates and margin assessment in pancreatic cancer.

M D Chandrasegaram1,2,3, D Goldstein4, J Simes1, V Gebski1, J G Kench5,6, A J Gill7, J S Samra8,6, N D Merrett9,3, A J Richardson10,6, A P Barbour11.   

Abstract

BACKGROUND: R0 resection rates (complete tumour removal with negative resection margins) in pancreatic cancer are 70-80 per cent when a 0-mm margin is used, declining to 15-24 per cent with a 1-mm margin. This review evaluated the R0 resection rates according to different margin definitions and techniques.
METHODS: Three databases (MEDLINE from 1946, PubMed from 1946 and Embase from 1949) were searched to mid-October 2014. The search terms included 'pancreatectomy OR pancreaticoduodenectomy' and 'margin'. A meta-analysis was performed with studies in three groups: group 1, axial slicing technique (minimum 1-mm margin); group 2, other slicing techniques (minimum 1-mm margin); and group 3, studies with minimum 0-mm margin.
RESULTS: The R0 rates were 29 (95 per cent c.i. 26 to 32) per cent in group 1 (8 studies; 882 patients) and 49 (47 to 52) per cent in group 2 (6 studies; 1568 patients). The combined R0 rate (groups 1 and 2) was 41 (40 to 43) per cent. The R0 rate in group 3 (7 studies; 1926 patients) with a 0-mm margin was 72 (70 to 74) per cent The survival hazard ratios (R1 resection/R0 resection) revealed a reduction in the risk of death of at least 22 per cent in group 1, 12 per cent in group 2 and 23 per cent in group 3 with an R0 compared with an R1 resection. Local recurrence occurred more frequently with an R1 resection in most studies.
CONCLUSION: Margin clearance definitions affect R0 resection rates in pancreatic cancer surgery. This review collates individual studies providing an estimate of achievable R0 rates, creating a benchmark for future trials.
© 2015 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26350029     DOI: 10.1002/bjs.9892

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  44 in total

1.  Can post-hoc video review of robotic pancreaticoduodenectomy predict portal/superior mesenteric vein margin status in pancreatic adenocarcinoma?

Authors:  Jae P Jung; Mazen S Zenati; Ahmad Hamad; Melissa E Hogg; Richard L Simmons; Amer H Zureikat; Herbert J Zeh; Brian A Boone
Journal:  HPB (Oxford)       Date:  2018-11-28       Impact factor: 3.647

2.  Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer.

Authors:  Masayuki Tanaka; Yosuke Inoue; Kiyoshi Matsueda; Makiko Hiratsuka; Mariko Muto; Shoji Kawakatsu; Yoshihiro Ono; Yoshihiro Mise; Takeaki Ishizawa; Hiromichi Ito; Yu Takahashi; Yutaka Takazawa; Akio Saiura
Journal:  J Gastrointest Surg       Date:  2019-04-01       Impact factor: 3.452

Review 3.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Authors:  Mustafa Suker; Berend R Beumer; Eran Sadot; Lysiane Marthey; Jason E Faris; Eric A Mellon; Bassel F El-Rayes; Andrea Wang-Gillam; Jill Lacy; Peter J Hosein; Sing Yu Moorcraft; Thierry Conroy; Florian Hohla; Peter Allen; Julien Taieb; Theodore S Hong; Ravi Shridhar; Ian Chau; Casper H van Eijck; Bas Groot Koerkamp
Journal:  Lancet Oncol       Date:  2016-05-06       Impact factor: 41.316

Review 4.  [R1 resection for pancreatic carcinoma].

Authors:  G F Weber; S Kersting; F Haller; R Grützmann
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

5.  Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety.

Authors:  Yosuke Inoue; Akio Saiura; Atsushi Oba; Shoji Kawakatsu; Yoshihiro Ono; Takafumi Sato; Yoshihiro Mise; Takeaki Ishizawa; Yu Takahashi; Hiromichi Ito
Journal:  J Gastrointest Surg       Date:  2018-10-10       Impact factor: 3.452

6.  Tumour origin and R1 rates in pancreatic resections: towards consilience in pathology reporting.

Authors:  Munita Bal; Swapnil Rane; Sanjay Talole; Mukta Ramadwar; Kedar Deodhar; Prachi Patil; Mahesh Goel; Shailesh Shrikhande
Journal:  Virchows Arch       Date:  2018-08-08       Impact factor: 4.064

7.  Pancreatic cancer: Clinical practice guidelines - what is the evidence?

Authors:  Oliver Strobel; Markus W Büchler
Journal:  Nat Rev Clin Oncol       Date:  2016-08-17       Impact factor: 66.675

8.  Total compared with partial pancreatectomy for pancreatic adenocarcinoma: assessment of resection margin, readmission rate, and survival from the U.S. National Cancer Database.

Authors:  M J Passeri; E H Baker; I A Siddiqui; M A Templin; J B Martinie; D Vrochides; D A Iannitti
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

9.  International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer.

Authors:  Stijn van Roessel; Gyulnara G Kasumova; Joanne Verheij; Robert M Najarian; Laura Maggino; Matteo de Pastena; Giuseppe Malleo; Giovanni Marchegiani; Roberto Salvia; Sing Chau Ng; Susanna W de Geus; Sanne Lof; Francesco Giovinazzo; Jacob L van Dam; Tara S Kent; Olivier R Busch; Casper H van Eijck; Bas Groot Koerkamp; Mohammed Abu Hilal; Claudio Bassi; Jennifer F Tseng; Marc G Besselink
Journal:  JAMA Surg       Date:  2018-12-19       Impact factor: 14.766

10.  Determinants of Outcomes Following Resection for Pancreatic Cancer-a Population-Based Study.

Authors:  Mary A Waterhouse; Elizabeth A Burmeister; Dianne L O'Connell; Emma L Ballard; Susan J Jordan; Neil D Merrett; David Goldstein; David Wyld; Monika Janda; Vanessa L Beesley; Madeleine E Payne; Helen M Gooden; Rachel E Neale
Journal:  J Gastrointest Surg       Date:  2016-05-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.